Cartesian Therapeutics (RNAC) Asset Utilization Ratio (2016 - 2025)
Cartesian Therapeutics (RNAC) has disclosed Asset Utilization Ratio for 10 consecutive years, with 0.0 as the latest value for Q4 2025.
- On a quarterly basis, Asset Utilization Ratio fell 98.62% to 0.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.0, a 98.62% decrease, with the full-year FY2025 number at 0.0, down 98.94% from a year prior.
- Asset Utilization Ratio was 0.0 for Q4 2025 at Cartesian Therapeutics, up from 0.0 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.76 in Q2 2022 to a low of 0.0 in Q3 2025.
- A 5-year average of 0.3 and a median of 0.21 in 2021 define the central range for Asset Utilization Ratio.
- Peak YoY movement for Asset Utilization Ratio: skyrocketed 442.99% in 2021, then crashed 100.96% in 2025.
- Cartesian Therapeutics' Asset Utilization Ratio stood at 0.52 in 2021, then rose by 23.74% to 0.64 in 2022, then crashed by 80.35% to 0.13 in 2023, then tumbled by 31.35% to 0.09 in 2024, then plummeted by 98.62% to 0.0 in 2025.
- Per Business Quant, the three most recent readings for RNAC's Asset Utilization Ratio are 0.0 (Q4 2025), 0.0 (Q3 2025), and 0.0 (Q2 2025).